Xencor, Inc Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
Xencor, Inc (XNCR) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $365.20 million as of 2024-06-30, per its 10-Q/A filed 2025-02-24.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2025-02-27
- 2024-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $365.20M.
- 2024-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $161.40M.
- 2023-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $74.62M.
- 2023-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $362.22M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months as first filed |
|---|---|---|
| 2024-06-30 | $365.20M 10-Q/A · filed 2025-02-24 | |
| 2024-03-31 | $161.40M 10-Q/A · filed 2025-02-24 | |
| 2023-12-31 | $74.62M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $362.22M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $343.16M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $351.26M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $457.59M 10-K/A · filed 2025-02-24 | |
| 2022-09-30 | $475.03M 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $364.46M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $224.60M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $90.25M 10-K · filed 2023-02-27 | |
| 2021-09-30 | $21.73M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $11.72M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $4.10M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $56.65M 10-K · filed 2022-02-24 | |
| 2019-12-31 | $46.30M 10-K · filed 2020-02-25 | |
| 2019-09-30 | $18.64M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $52.23M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $318.50M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $260.89M 10-K · filed 2020-02-25 | $268.12M 10-K · filed 2019-02-26 |
| 2018-09-30 | $236.60M 10-Q · filed 2018-11-05 | |
| 2017-12-31 | $207.60M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |